Category: New products
-
AI Recreates Tumor Environment for Precision Cancer Care
A bioinformatics company designed an algorithm that digitally recreates the support network for tumors from RNA sequences, to guide precise treatments for cancer patients.
-
Synthetic Bio Chemicals Start-Up Gains $5M in Early Funds
A new enterprise using digital and synthetic biology to create sustainable chemicals at industrial scale is raising $5 million in pre-seed round funds.
-
Infant Gut Microbiome Biomarker Study Underway
A clinical study has begun analyzing infants’ stool samples to determine the characteristics of healthy microbial communities in young children.
-
Univ. Labs Ink Licensing Deals for Covid-19 Tests
Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections.
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
Peptide Vaccine Shown to Reduce Harmful Cholesterol
Tests with lab monkeys show a vaccine with a synthetic peptide lowers so-called bad cholesterol in blood for longer periods than a comparable monoclonal antibody.
-
Alzheimer’s Assn Collecting Real-World Therapy Data
An advocacy group for Alzheimer’s disease care and research is establishing a network for collecting long-term safety and outcomes data from patients in real-world settings.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Biotechs Discover Antimicrobial Peptide for Food Safety
Two biotechnology companies say they discovered a peptide molecule with antimicrobial properties for faster identification and containment of food contamination outbreaks.
-
Small Biz Grant Funds Non-Viral Gene Editing Delivery
National Institutes of Health is financing a delivery method for gene-editing therapies to blood-forming stem cells with natural lipid bubbles instead of viruses.